CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause

About this update from Crossject Sa

[{"type":"image","alt":"CROSSJECT","displaySize":"","headline":null,"caption":"CROSSJECT","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/5049eda363ac301cbfd1577dab53d65a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rK9m607pcnIrkhBB4D_IFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5049eda363ac301cbfd1577dab53d65a","width":200,"height":87}},"lazy":false},{"type":"text","content":"Press release","length":13,"tagName":"p"},{"type":"text","content":"CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause","length":113,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Transaction raised to over 5.7 million euros following full exercise of the extension clause.","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Total demand of over 9,2 million euros, representing an oversubscription rate of 1.84x.","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"Transaction benefited from the support of Gemmes Venture and investment by new investor Vatel Capital.","length":102,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":282,"olType":false},{"type":"text","content":"Dijon, France June 24, 2025 (7.00 PM CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharmaceutical company in late-stage clinical and regulatory development of ZEPIZURE®, its emergency treatment for the management of epileptic seizures based on the award-winning ZENEO® needle-free auto-injector, announces the successful completion of its capital increase with preferential subscription rights ("DPS"), for a gross amount of 5,725,479.20 euros after full exercise of the extension clause and for a net amount of approximately 5,458,093.69 (the "Offer").","length":597,"tagName":"p"},{"type":"text","content":"This financing is an important step in the final registration phases of ZEPIZURE® and the continuation of initial commercial production stages. The transaction was carried out at a subscription price of 1.40 euros, representing a 22.6% discount to the closing price on June 3, 2025.","length":282,"tagName":"p"},{"type":"text","content":"Patrick ALEXANDRE, Chairman of the Management Board, comments: &quo...

More updates from Crossject Sa